Leukeran (Chlorambucil)

Chlorambucil works by covalently binding to DNA bases, creating intra‑ and interstrand cross‑links. These cross‑links block DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, especially in rapidly dividing malignant lymphocytes.

The dosage of Leukeran is individualized. A qualified prescriber determines the appropriate dose, schedule, and duration based on the patient’s specific condition, disease stage, and laboratory parameters. No standard dose is provided here.

Safety data for chlorambucil during pregnancy and lactation are limited. Because potential risks to the fetus or infant are unknown, the drug is generally avoided in pregnant or breastfeeding women unless the potential benefit justifies the risk.

To order Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Leukeran (chlorambucil) is an oral alkylating agent, whereas alternatives such as cyclophosphamide are also alkylators but are often given intravenously. Chlorambucil generally has a milder toxicity profile but may be less potent in some aggressive lymphomas, making choice dependent on disease characteristics and patient tolerance.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Leukeran is taken orally as a tablet, usually with a full glass of water. It may be taken with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

The most serious risks include severe bone‑marrow suppression leading to infections or bleeding, secondary malignancies such as acute leukemia, significant liver toxicity, and rare pulmonary complications. Patients should be monitored closely for signs of infection, abnormal bleeding, or respiratory symptoms.

Leukeran should not be used by individuals with known hypersensitivity to chlorambucil or other alkylating agents, patients with severe bone‑marrow failure, pregnant or breastfeeding women, and those with uncontrolled infections unless the benefits outweigh the risks.